NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Equally important, but under appreciated, overall survival at five years for DCVax-l treating patients with significant residual disease, was equal to DCVax-l treating minimum residual disease patients. Both have essentially 13% five year survival, and both have almost 11% patients at risk — at five years.

mOS was 17.5 vs 20.4 months. between the -L resection groups.
5yOS was 14 vs 11% (I took the time to put the graphs into a digitizer).

Those are not the same.

The fact is that the near total resection populations where there was no resection bias showed no improvement. The others, where there was significant resection bias, was where all the improvement was shown.

As far as the mess . argument, that is just hand waving.